The first to go under were the small companies since the cure was released.It started with quiet conversations on the trading floors,confused whispers that quickly spiraled into chaos.
The initial casualties were mid-sized suppliers in oncology, their survival reliant on a demand for treatments that no longer existed. They had amassed their wealth on gradual cures and lengthy treatment regimens, but now, one new pill rendered all of that useless.
By the third week following the launch of LUCEM-9, hundreds of these firms were out of business. Their stocks were delisted, their offices locked up, and employees packed their belongings into boxes, leaving under a dreary sky.
Yet, with their downfall, market stability remained elusive. Instead, the markets quaked even more. In the bustling trading rooms across Panterra, thousands of brokers traversed the chaos like ants caught in a storm.
The air was filled with the noise of ringing phones, tapping keyboards, and shouting voices.
